• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Brazil: 2024-2026 Mpox

Shiloh

Editor, Senior Moderator
Source: https://portalplural.com.br/mpox-br...e-o-comeco-do-ano-e-ultrapassa-marca-de-2023/

Mpox: Brazil records 945 cases since the beginning of the year and surpasses the 2023 mark
Published 9 hours ago
on September 4, 2024
By Bruna Dourado Stieler

On Tuesday (3), the Ministry of Health released the weekly report on mpox cases in Brazil. Since the beginning of the year, 945 confirmed or probable cases of the disease have been recorded, surpassing the 853 cases last year.

According to the bulletin, 109 new confirmed or probable cases were reported last week alone. The Southeast region is the most affected, with 763 cases, which represents 80.7% of the total in the country.

The states with the highest number of confirmed or probable cases are:

São Paulo: 487 cases (51.5%)
Rio de Janeiro: 216 cases (22.9%)
Minas Gerais: 52 cases (5.5%)
Bahia: 39 cases (4.1%)

The bulletin also reports that no cases were recorded in three states: Amapá, Tocantins and Piauí.

The cities with the highest number of confirmed or probable cases are:

São Paulo: 343 cases (36.3%)
Rio de Janeiro: 160 cases (16.9%)
Belo Horizonte: 43 cases (4.6%)
Salvador: 28 cases (3.0%)
Brasília: 20 cases (2.1%)

So far, there have been no deaths from mpox this year. In 2023, two deaths were recorded, one in Minas Gerais and the other in Pará. In 2022, there were 14 deaths, with five occurring in Rio de Janeiro, three in São Paulo, three in Minas Gerais and one in each of the states of Maranhão, Mato Grosso and Santa Catarina...​
 
Source: https://www.vax-before-travel.com/2025/03/11/mpox-clade-1b-arrives-sao-paulo

Mpox Clade 1b Arrives in Sao Paulo
March 11, 2025 • 8:33 am CDT​

(Vax-Before-Travel News)

The Ministry of Health for the State of São Paulo recently confirmed its first patient infected with Mpox Clade 1b. The infection was confirmed in early March 2025 in an adult woman in the Metropolitan Region of São Paulo.

According to the media statement of March 10, 2025, she is expected to be discharged next week.

The patient had not traveled to outbreak areas in Africa but had contact with individuals from the Democratic Republic of Congo, where the virus is endemic.​..
 
Translation Google

HEALTH SURVEILLANCE

Mpox cases and deaths in Brazil are approximately 90% lower than those recorded in 2022

The Ministry of Health, with the support of states and municipalities, is monitoring the situation nationwide and increasing vaccine distribution to areas with the highest number of cases.

Published on 11/16/2026, 6:51 PM | Updated on 11/17/2026, 6:46 PM

In 2026, Brazil has recorded 1,055 confirmed cases of mpox—a decrease of approximately 90% compared to the 10,591 cases tallied in 2022, when the country experienced the peak of the disease. Since then, the Unified Health System (SUS) has maintained a network for diagnosis, treatment, and monitoring across the entire country. The Ministry of Health works in coordination with states and municipalities and maintains a strategic stockpile of vaccines for groups at higher risk of developing severe forms of the disease.

This year, one death was recorded in October, in the city of Rio de Janeiro. In 2022, there were 14 deaths, representing a 92.9% reduction. Of the 1,055 confirmed cases, 74.8% are concentrated in São Paulo (398) and Rio de Janeiro (391). These are followed by Ceará (60), Minas Gerais (41), and the Federal District (39). To ensure vaccination for priority groups, 3,850 doses were shipped in November: 2,000 to Rio de Janeiro, 500 to Bahia, 400 to Ceará, 300 to Piauí, 250 to Paraná, and 100 to each of the following states: the Federal District, Paraíba, Amapá, and Goiás. Shipments are based on the quantities requested by state health departments, which are responsible for distributing the doses to municipalities.

Since the beginning of the year, more than 15,600 doses have been distributed to the states, 12,200 of which have been administered. The vaccine is in limited supply due to a global shortage; there is only one manufacturer, located in Denmark, which is pre-qualified by the World Health Organization (WHO).

Given this situation, the Ministry of Health—through the Pan American Health Organization (PAHO) Revolving Fund—negotiated the delivery of 25,000 doses from the Danish manufacturer, representing their entire available stock. The vaccine requires specific logistical and storage conditions: it must be kept frozen at –20°C, and once thawed, the doses must be administered within four weeks. Consequently, states request new shipments from the Ministry of Health as their existing stocks run low.

Who is eligible to receive the vaccine?

In accordance with World Health Organization (WHO) guidelines, the SUS (Brazil’s Unified Health System) does not conduct mass vaccination against mpox. Vaccination is recommended for people living with HIV/AIDS with a CD4 count below 100 cells/mm³, with a gradual expansion to other groups at higher vulnerability or risk of exposure to the disease: people living with HIV with a CD4 count below 200 cells/mm³, PrEP users, laboratory professionals who handle mpox samples, and individuals aged 18 to 49 who have had medium- or high-risk exposure to suspected, probable, or confirmed cases of the disease. The regimen consists of two doses, administered 28 days apart.

The protocol requires two doses, with an interval of 28 days. Vaccination is not provided at Basic Health Units (UBS); individuals in the target groups should contact the specialized healthcare facility where they already receive care to register and schedule an appointment.

Last week, the Ministry of Health instructed states and municipalities to adopt an intradermal administration method for the vaccine. This strategy, already in use in Europe, allows for up to a fivefold increase in the number of people who can be vaccinated with a single dose of the vaccine, within specific groups.

Transmission and prevention

Transmission occurs primarily through close contact with infected individuals, and cases are concentrated mainly in large urban centers. The primary symptoms include skin lesions (rashes), fever, swollen lymph nodes, headache, body aches, chills, and weakness.

Vaccination does not replace preventive measures and precautions taken to avoid the transmission of the virus. It is important to avoid direct contact with individuals suspected or confirmed to have the disease, practice hand hygiene, wash clothing, towels, and bed linens, and clean frequently used surfaces and objects. Anyone who has had close contact with an infected person should seek guidance from a healthcare service.

Ministry of Health

Category
Health and Sanitary Surveillance

 
Back
Top Bottom